Patient Focused Drug Development (PFDD)
Allergy & Asthma Network has been a proud collaborator for three Patient-Focused Drug Development (PFDD) meetings for allergy, asthma and related conditions:
- Childhood asthma – 2021
- Food allergy – 2021
- Atopic dermatitis (eczema) – 2019
What is Patient-Focused Drug Development?
Patient-focused drug development is an ongoing initiative by the U.S. Food and Drug Administration (FDA). PFDD meetings are a way to help inform the FDA about what’s important to patients about drug development including:
- their experiences;
- their perspectives;
- their needs;
- their priorities.
The FDA uses these insights to inform the drug development and evaluation process.
Patient groups petition the FDA to organize externally-led PFDD meetings. Patient groups then hold a public meeting to share with the FDA patient perspectives about:
- the symptoms that patients find most significant;
- the impact of their condition on their daily lives;
- what is important to them about current and future treatments.
Since 2012, the FDA has worked with patient groups to hold more than 70 PFDD meetings on chronic and rare diseases.
PFDD meetings lead to the publication of a summary report. These are often called the “Voice of the Patient” report. The patient groups hosting the meeting present the report to the FDA after the meeting. The report summarizes what is important to patients when it comes to current and future treatments.
The FDA can use this report to inform the patient perspective for the drug development and evaluation process.
See Related Pages
- Patient Focused Drug Development (PFDD)
- Allergy and Asthma Research – Published Literature
- Allergy and Asthma Research Projects and Partnerships
- Get Involved with Research for Allergy, Asthma, and Related Diseases
- Asthma Registry
- COVID-19 Registry